Kala Bio (LTS:0JQ2) Total Noninterest Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0JQ2 Kala Bio Inc LTS:0JQ2
29 GF Score
Price $0.74
GF Value $1.98
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Kala Bio Total Noninterest Expense?

Total Noninterest Expense only applies to banks.

LTS:0JQ2
29GF Score
Kala Bio Inc LTS:0JQ2
Total Noninterest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Kala Bio (LTS:0JQ2) Overvalued in 2026?

Based on GuruFocus' analysis, Kala Bio stock appears to be undervalued. The current stock price of $0.74 is trading 62.6% below its estimated GF Value™ of $1.98. GuruFocus considers Kala Bio to be Significantly Undervalued.

Key valuation signals for LTS:0JQ2:

  • Total Noninterest Expense:
  • GF Value™: $1.98 vs. price of $0.74 (62.6% below fair value)
  • GF Score™: 29/100 with 1 warning sign

No single metric tells the full story. See the LTS:0JQ2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kala Bio Business Description

Other Exchanges KALA:USA27F:Germany
Address 1167 Massachusetts Avenue, Arlington, MA, USA, 02476
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
29GF Score

Get the complete analysis for LTS:0JQ2

Total Noninterest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.74
Price
$1.98
GF Value